Adicet Bio, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Adicet Bio reported Q2 2026 net loss of $21.4 million ($1.99 per share) on R&D spend of $18.5M and G&A of $3.9M. Cash position of $118.2M (down from $158.5M at year-end 2025) supports operations into H2 2027. Clinical milestones: prula-cel Phase 1 update (22 LN/SLE patients, 13 with 12+ months follow-up) now expected Q3 2026; FDA alignment achieved on pivotal trial design for lupus nephritis with startup planned H2 2026; ADI-212 regulatory submission expected Q3 2026, Phase 1 enrollment Q4 2026. CMO Julie Maltzman departed; Lloyd Klickstein (board member) appointed Interim CMO.
Why this rating
Clinical delays and cash burn are concerning but runway extends to H2 2027. Pipeline advancement on track. Cash of $118M is ~235% of market cap, mitigating near-term risk but dilution likely.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.